BioXcel Therapeutics, Inc. (BTAI) Covered Calls

You can sell covered calls on BioXcel Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for BTAI (prices last updated Wed 4:16 PM ET):

BioXcel Therapeutics, Inc. (BTAI) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
2.71 -0.26 2.71 2.78 880K - 0.1
Covered Calls For BioXcel Therapeutics, Inc. (BTAI)
Expiration Strike Call Bid Net Debit Return
If Flat
Annualized
Return If Flat
May 17 2.5 0.00 2.78 -10.1% -153.6%
Jun 21 2.5 0.00 2.78 -10.1% -62.5%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial


Extended Business Description

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent for the treatment of prostate and pancreatic cancers, and other solid tumors. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA; Nektar Therapeutics, Inc.; and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.